Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001844664 | SCV002103871 | uncertain significance | not specified | 2022-02-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002543324 | SCV003454038 | likely benign | Spastic paraplegia | 2024-02-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163995 | SCV003904435 | uncertain significance | Inborn genetic diseases | 2023-03-01 | criteria provided, single submitter | clinical testing | The c.13621T>A (p.L4541M) alteration is located in exon 10 (coding exon 9) of the SACS gene. This alteration results from a T to A substitution at nucleotide position 13621, causing the leucine (L) at amino acid position 4541 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Neuberg Centre For Genomic Medicine, |
RCV003339758 | SCV004047554 | uncertain significance | Charlevoix-Saguenay spastic ataxia | criteria provided, single submitter | clinical testing | The missense variant c.13621T>A (p.Leu4541Met) in SACS gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The p.Leu4541Met variant has allele frequency 0.002% in gnomAD exomes and novel (not in any individuals) in 1000 Genomes. This variant has reported to the ClinVar database as Uncertain Significance. The amino acid Leu at position 4541 is changed to a Met changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Leu4541Met in SACS is predicted as conserved by PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Uncertain Significance (VUS). |